Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
ImmUniverse logo


Start Date
End Date
IMI2 - Call 15
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
15 500 000
EFPIA in kind
15 500 000
110 000
Total Cost
31 110 000


Immune-mediated diseases are extremely diverse – patients with the same diagnosis may see the disease progress in very different ways, and respond differently to treatments. This is because the course of the disease is influenced by multiple factors, including the patient’s genes, immune system, environment, and the microbes living in their gut. Furthermore, all of these factors interact with and impact on one another. As a result, it is very hard to predict how the disease will develop in a specific patient, and which treatments will be effective.

The goal of ImmUniverse is to add to our understanding of two immune-mediated diseases: ulcerative colitis (in which the immune system attacks the colon), and atopic dermatitis (which affects the skin). It will use liquid biopsies to detect the immune cells circulating in the blood, and analyse how these interact with the tissues affected at the microenvironment scale. The project will follow a number of patients over time to see how the disease evolves.

Ultimately, the project’s findings should contribute to a better, more precise diagnosis for patients; and better information on how severe the disease is likely to be for each individual patient and how it will progress over time. Finally, the project will make it easier for doctors and patients to monitor how well a treatment is working.

Participants Show participants on map

EFPIA companies
  • Eli Lilly And Company LTD, Basingstoke, United Kingdom
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Aarhus Universitet, Aarhus C, Denmark
  • Aarhus Universitetshospital, Aarhus, Denmark
  • Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
  • Ait Austrian Institute Of Technology GMBH, Wien, Austria
  • Centre Hospitalier Regional Universitaire Nancy, Nancy Cedex, France
  • Christian-Albrechts-Universitaet Zu Kiel, Kiel, Germany
  • Forum Des Patients Europeens, 1040, Belgium
  • Humanitas University, Pieve Emanuele, Italy
  • Istituto Superiore Di Sanita, Roma, Italy
  • Joanneum Research Forschungsgesellschaft Mbh, Graz, Austria
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna, Pisa, Italy
  • Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
  • Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg
  • University of Cambridge, Cambridge, United Kingdom
  • Vib Vzw, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Eurice European Research And Project Office GMBH, Saarbrücken, Germany
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
Patient organisations
  • European Federation Of Asthma &Allergy Associations Ideell Forening, Brussels, Belgium
  • European Federation Of Crohn'S And Ulcerative Colitis Associations, Bruxelles, Belgium
Third parties
  • Humanitas Mirasole S.A, Rozzano (Mi), Italy
Project coordinator
Stefania Vetrano
Humanitas University